据证券之星公开数据整理，近期特一药业（002728）发布2025年中报。截至本报告期末，公司营业总收 入4.91亿元，同比上升56.54%，归母净利润3800.77万元，同比上升1313.23%。按单季度数据看，第二 季度营业总收入1.96亿元，同比上升31.43%，第二季度归母净利润644.05万元，同比上升199.62%。本 报告期特一药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达 39.42%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率60.23%，同比增52.27%，净利率7.74%，同比增 802.78%，销售费用、管理费用、财务费用总计2.27亿元，三费占营收比46.27%，同比增39.42%，每股 净资产3.46元，同比减3.35%，每股经营性现金流0.29元，同比增441.35%，每股收益0.08元，同比增 1500.0% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 3.14亿 | 4.91亿 | 56.54% | | 归母净利润(元) | 268.94万 | ...

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, with all board members assuming legal responsibility for any misstatements or omissions [2][3] - The first quarter report has not been audited, and the company has made retrospective adjustments to previous accounting data [3][4] Financial Data - The core product, cough relief tablets, achieved sales of 217 million pieces, with brand building investments reaching 106 million yuan [4] - The company is undergoing marketing organizational changes and brand marketing construction, which have shown initial results but may pose risks to short-term operating performance [4][5] Shareholder Information - The report includes details on the total number of common stock shareholders and the top ten shareholders, although there are no changes in the lending of shares for the top shareholders [4]